New hope for MASH: phase 3 trial aims to shrink liver fat
NCT ID NCT07581951
First seen May 20, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study tests a new medicine called HSK31679 for people with MASH, a serious liver condition linked to metabolic issues. About 400 adults will receive either the drug or a placebo for 52 weeks to see if it safely reduces liver fat. The goal is to find a treatment that controls the disease and prevents it from getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.